$AKBA LongAkebia recent selloff not based on fundamentals, says H.C. Wainwright H.C. Wainwright analyst Ed Arce no...

Great coverage from you this am admdr5. $AKBA remains as close to a sure thing as one gets in biotech. It and Fibrogen w...

$TEVA np - seeking partners to fund some drug development- Reuters https://twitter.com/odibro/status/8977676779173765...

$AKAB. LongAkebia Therapeutics announces the EPO has revoked FibroGen's (FGEN) HIF-related patent in Europe and anno...

Hi lev: This is another situation where two companies are in a race and vying for the same space: here it's Cambridge-ba...

Puts $AKBA ahead by a nose vs FibroGen. Long $AKBA. Company pretty gapingly undervalued here....

In the Akebia vs FibroGen faceoff, I've always backed Akebia, as per our 2014 column. Better agent, better science. (I s...

Hi Zimmy: I'm pretty strongly confident in the abilities of the drugs of both Fibrogen and Akebia to really wring out th...

Dr. KSS MD PhD, author of this article, says: October 2, 2015 at 10:43 am http://www.stockgumshoe.com/2015/09/the-tao-of...

glenn newberry says: August 28, 2015 at 5:08 pm http://www.stockgumshoe.com/2015/08/cellceutix-23-minutes-with-leo-ehrli...

ans_chandra says: May 20, 2015 at 8:26 pmhttp://www.stockgumshoe.com/2015/05/cisco-chang-charlie/comment-page-3/#commen...

Fibrogen - February 16, 2015 at 3:41 pm http://www.stockgumshoe.com/2015/02/saving-jack-kerouac/comment-page-4/#comment-...

Fibrogen: http://www.stockgumshoe.com/2014/06/microblog-is-this-red-hot-new-blood-stock-any-bloody-good-as-an-investmen...

Dr. KSS, MD PhD says: January 5, 2015 at 5:49 pm http://www.stockgumshoe.com/2014/12/the-finale-is-grand-the-gain-from-...

$FGEN- FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients Wit...

AGEN, AKBA, PIRS, FLKS: Extracted from: http://www.thelifesciencesreport.com/pub/na/panelists-select-19-companies-for-t...

Hi Dan: no real catalyst so much as chatter about how undervalued it is, that investors are starting to notice it's been...

It appears that Akebia (AKBA) came out on top of this patent ruling with main competitor Fibrogen (FGEN) today. Long AKB...

UBS reiterates buy rating today on $AKBA, with 12 mo PT in line with mine of $16....this is premised on a 40 percent cha...

Long case for Receptos Dr. KSS, MD PhD, author of this article, says: February 2, 2015 at 6...

Re: $FGEN Have we discussed Fibrogen here before? If yes then please point me to the comment(s). I couldn't find it in ...

Since this article was about GILD and there was mention of Simtuzumab, I'm going to take this chance and ask a few quest...

Since the time of last year's column on $AKBA, it has overcome the main objection, which was that then it was too expens...

Thanks Om. Good to know. FibroGen, which recently went public and has a competing agent, was up 20-odd percent today. I ...

ockrazor on Dawn of the Planet of the TLOGlodytes! / Dec 9, 12:27pm

From RBC this Am. No position just sharing. Eyedoc just heard on Squawk that sanofi was looking at Petmed takeover. I b...

DrKSSMDPhD on Payola from Portola? / Nov 26, 1:52pm

JP...thanks. So obviously a volcano is going to pop here. Probably +phase 2 data for their HIF drug. I may have to get i...

Jeffrey M on Payola from Portola? / Nov 14, 3:01pm

After reading Dr KSS's comments on Fibrogen ($FGEN) in the article that he references above, I'm seriously thinking abou...

DrKSSMDPhD on Tetchy on Tekmira: Time to Short this RNAi Play? / Oct 1, 6:11pm

Hi: ironically, just a little while ago, I was speaking with someone who tells me that FibroGen has just been socked wit...

DrKSSMDPhD on Is This Red-Hot New “Blood Stock” Any Bloody Good as an Investment? / Jun 18, 6:34pm

Thanks Vivian. I have a healthy respect for the company and will be watching/following. If phase 2 succeeds and they iss...